Syndivia’s GeminiMab Wins “Best Drug-Based Innovation” Award from MATWIN Board

STRASBOURG (France) – May 23, 2024 – Syndivia is proud to announce that its GeminiMab technology – the first and only hinge site-specific conjugation platform enabling next-generation DAR1 and low-DAR ADCs – has been awarded Best Drug-Based Innovation by the MATWIN Board.

This recognition comes from a prestigious panel comprising representatives of 13 major pharmaceutical companies alongside leading academic and industry experts, highlighting the growing impact of GeminiMab on the future of ADC design, dosing, and therapeutic index.

The award acknowledges the unique ability of GeminiMab to generate stable, native-antibody ADCs with optimized DAR and improved pharmacological performance. This distinction further strengthens the momentum around DAR1 ADCs and Syndivia’s approach to high-dosing, clinically scalable conjugates.

We extend our sincere thanks to MATWIN, the jury, and all collaborators who contributed to this achievement.

Syndivia remains committed to advancing the field of ADCs and looks forward to sharing more updates as our GeminiMab pipeline progresses.

For more information, you can download the full press release here: Download the press release.